admin

Late last month, shares in Nvidia (NASDAQ:NVDA) hit a new milestone. Thanks to the chipmaker’s post-earnings rally, NVDA stock entered “trillion dollar territory” for the first time. After climbing to prices above $404.85 per share, Nvidia’s market cap reached the $1 trillion mark. However, it is unclear right now whether NVDA is now a permanent

After a brutal 2022, Wall Street has fallen back in love with high-return aggressive growth stocks. Stocks with aggressive growth potential have outperformed value stocks by a wide margin so far in 2023, and there’s reason to believe this trend will continue. A major force behind the exodus from growth stocks last year was the

The stock market has roared back to life in 2023 and has largely outperformed expectations. Investors have begun to pour back into the stock market in search of bargains. However, despite high returns in growth stocks, investors are still highly interested in seeking lower-risk securities. A typical way to go about doing that is to

Artificial intelligence (AI) is a revolutionary technology that helps people access relevant information more quickly and increase their productivity. While OpenAI’s ChatGPT has taken center stage recently, many companies use AI in the background to improve their services and increase their revenue. Some high-potential AI stocks use this technology to make product recommendations, while other

Fintech stocks have continued trading sideways since the selloffs in late 2021 and currently offer some of the best entry points in the market. Most growth stocks have rebounded substantially this year, and fintech is among the only sectors that are still behind. I believe they will follow suit and rally in the coming months,

Identifying undervalued sleeper stocks will always be a great way to find strong returns in the market. As with all investments, you can only get out what you put in; reaching a million will take time. That said, the three names below can help you in your journey toward millionaire status. The market is again

Everyone is talking about artificial intelligence (AI) these days, and with good reason.  On Main Street, AI will reshape society. And on Wall Street, AI stocks will mint millionaires.  This is the internet boom of the early 1990s all over again.  At that time, this new thing called “the internet” was being heralded as the

Listen up, meme-stock traders! Video game retailer GameStop (NYSE:GME) is preparing to overhaul the company’s loyalty rewards program. This is a smart move that could bolster GameStop’s top-line results in 2023. In addition, GME stock might soar this year if regulators prohibit short selling. Is GameStop on the cusp of a comeback? It’s certainly possible as

Editor’s note: “‘Miracle’ Psychedelics Could Save Lives and Mint Millions” was previously published in March 2023. It has since been updated to include the most relevant information available. There has been a lot of negative news over the past year. A war in Europe. Inflation running at decade highs. Economic indicators suggesting an incoming recession. 

Many crypto investors will likely assert that no cryptos are better buys than Bitcoin (BTC-USD) or Ethereum (ETH-USD). To some extent, when measuring for risk-adjusted returns over the long-term, that argument holds water, as there are several high potential cryptos better than Bitcoin worth considering. However, not all investors are looking at crypto with the same investing time

Recently, United States President Joe Biden and House Republican Speaker Kevin McCarthy have tentatively agreed to raise the federal government’s $31.4 trillion debt ceiling. However, a no-deal scenario could significantly hurt the economy if the deal is voted not to pass by Congress starting on May 31st. Economists predict higher borrowing costs, loan interest rates, and

When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies